JP2018184462A5 - - Google Patents

Download PDF

Info

Publication number
JP2018184462A5
JP2018184462A5 JP2018144003A JP2018144003A JP2018184462A5 JP 2018184462 A5 JP2018184462 A5 JP 2018184462A5 JP 2018144003 A JP2018144003 A JP 2018144003A JP 2018144003 A JP2018144003 A JP 2018144003A JP 2018184462 A5 JP2018184462 A5 JP 2018184462A5
Authority
JP
Japan
Prior art keywords
hydroxycodeinone
composition according
ppm
content
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018144003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018184462A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018184462A publication Critical patent/JP2018184462A/ja
Publication of JP2018184462A5 publication Critical patent/JP2018184462A5/ja
Pending legal-status Critical Current

Links

JP2018144003A 2004-03-30 2018-07-31 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法 Pending JP2018184462A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60/557,492 2004-03-30
US60153404P 2004-08-13 2004-08-13
US60/601,534 2004-08-13
US62007204P 2004-10-18 2004-10-18
US60/620,072 2004-10-18
US64862505P 2005-01-31 2005-01-31
US60/648,625 2005-01-31
US65177805P 2005-02-10 2005-02-10
US60/651,778 2005-02-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017043530A Division JP6503392B2 (ja) 2004-03-30 2017-03-08 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法

Publications (2)

Publication Number Publication Date
JP2018184462A JP2018184462A (ja) 2018-11-22
JP2018184462A5 true JP2018184462A5 (enExample) 2019-01-10

Family

ID=35124996

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2007506507A Expired - Lifetime JP4912294B2 (ja) 2004-03-30 2005-03-30 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2011058728A Expired - Lifetime JP5118223B2 (ja) 2004-03-30 2011-03-17 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2011251260A Expired - Lifetime JP5378486B2 (ja) 2004-03-30 2011-11-17 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2012123160A Expired - Lifetime JP5543991B2 (ja) 2004-03-30 2012-05-30 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2014045713A Pending JP2014139205A (ja) 2004-03-30 2014-03-07 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2015108759A Pending JP2015187134A (ja) 2004-03-30 2015-05-28 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2017043530A Expired - Lifetime JP6503392B2 (ja) 2004-03-30 2017-03-08 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2018144003A Pending JP2018184462A (ja) 2004-03-30 2018-07-31 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法

Family Applications Before (7)

Application Number Title Priority Date Filing Date
JP2007506507A Expired - Lifetime JP4912294B2 (ja) 2004-03-30 2005-03-30 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2011058728A Expired - Lifetime JP5118223B2 (ja) 2004-03-30 2011-03-17 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2011251260A Expired - Lifetime JP5378486B2 (ja) 2004-03-30 2011-11-17 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2012123160A Expired - Lifetime JP5543991B2 (ja) 2004-03-30 2012-05-30 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2014045713A Pending JP2014139205A (ja) 2004-03-30 2014-03-07 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2015108759A Pending JP2015187134A (ja) 2004-03-30 2015-05-28 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法
JP2017043530A Expired - Lifetime JP6503392B2 (ja) 2004-03-30 2017-03-08 25ppm未満の14−ヒドロキシコデイノンを有するオキシコドンハイドロクロライドの調製方法

Country Status (38)

Country Link
US (35) US7129248B2 (enExample)
EP (7) EP2311839A1 (enExample)
JP (8) JP4912294B2 (enExample)
KR (12) KR20140021716A (enExample)
CN (5) CN102838607B (enExample)
AP (1) AP2232A (enExample)
AR (1) AR049012A1 (enExample)
AT (2) ATE501150T1 (enExample)
AU (2) AU2005230826C1 (enExample)
BR (1) BRPI0508758B8 (enExample)
CA (3) CA2913355C (enExample)
CR (2) CR8593A (enExample)
CY (5) CY1111487T1 (enExample)
DE (2) DE602005026786D1 (enExample)
DK (6) DK2319846T3 (enExample)
EA (1) EA013208B1 (enExample)
EC (1) ECSP066953A (enExample)
ES (6) ES2566363T3 (enExample)
FI (1) FI7843U1 (enExample)
HR (5) HRP20110425T4 (enExample)
HU (3) HUE036451T2 (enExample)
IL (8) IL178038A (enExample)
LT (2) LT2316837T (enExample)
MA (1) MA28492B1 (enExample)
ME (4) ME01299B (enExample)
MX (2) MX363228B (enExample)
MY (3) MY172063A (enExample)
NO (1) NO337669B1 (enExample)
NZ (3) NZ549430A (enExample)
PE (1) PE20050880A1 (enExample)
PL (5) PL2319846T3 (enExample)
PT (5) PT2305683E (enExample)
RS (5) RS57000B1 (enExample)
SG (3) SG170735A1 (enExample)
SI (5) SI2316837T1 (enExample)
TW (3) TWI365880B (enExample)
WO (1) WO2005097801A1 (enExample)
ZA (1) ZA200607181B (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
ATE365545T1 (de) * 2003-08-06 2007-07-15 Gruenenthal Gmbh Gegen missbrauch gesicherte darreichungsform
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
ME01594B (me) * 2005-03-04 2014-09-20 Euro Celtique Sa Postupak smanjenja alfa, beta nezasićenih ketona u opioidnim kompozicijama
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
KR101417135B1 (ko) * 2005-11-22 2014-07-08 콘드롤드 케미컬즈, 인크. 옥시코돈 및 다른 조성물에서 오염물질인 마이클 수용체수준을 감소시키는 방법
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
CN101395159A (zh) 2006-03-02 2009-03-25 马林克罗特公司 制备含有低含量α,β-不饱和酮化合物的吗啡烷-6-酮产物的方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2674915C (en) 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
DK2073636T3 (da) * 2006-10-17 2012-11-19 Penick Corp Fremgangsmåde til fremstilling af oxymorphon
CA2671518C (en) 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
ES2378710T3 (es) * 2006-12-04 2012-04-17 Noramco, Inc. Procedimiento para reducir impurezas en la base de oxicodona
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2681740A1 (en) * 2007-03-23 2008-10-02 Mallinckrodt Inc. Improved preparation of oxymorphone from oripavine
ES2423180T3 (es) * 2007-04-16 2013-09-18 Mallinckrodt Llc Nueva reducción de opiáceos mediante reacción de transferencia de hidrógeno catalítica
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
AU2009294308B2 (en) * 2008-09-18 2013-05-30 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(e-caprolactone)
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) * 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
NZ598922A (en) * 2009-08-31 2014-03-28 Depomed Inc Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
CN102821757B (zh) * 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
BR112012028773A2 (pt) 2010-05-10 2016-07-19 Euro Celtique Sa composições farmacêuticas compreendendo hidromorfona e naloxona
CA2798885C (en) 2010-05-10 2014-11-18 Euro-Celtique S.A. Combination of active loaded granules with additional actives
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
EP2580201B1 (en) 2010-06-11 2017-08-02 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
TWI471289B (zh) 2010-06-11 2015-02-01 Rhodes Technologies 使三級胺進行n-脫烷反應之方法
EP2588481B1 (en) 2010-07-02 2017-11-15 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
US9414988B2 (en) 2011-09-05 2016-08-16 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
US20140294947A1 (en) 2011-09-16 2014-10-02 Purdue Pharma L.P. Tamper resistant immediate release formulations
ES2641437T3 (es) 2011-09-16 2017-11-10 Purdue Pharma Lp Formulaciones farmacéuticas resistentes a la manipulación indebida
CN104010630A (zh) 2011-12-09 2014-08-27 普渡制药公司 包含聚(ε-己内酯)和聚氧乙烯的药物剂型
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PE20142320A1 (es) 2012-03-02 2015-01-16 Rhodes Pharmaceuticals Lp Formulaciones de liberacion inmediata resistentes a la manipulacion
MX2014011855A (es) 2012-04-17 2016-09-09 Purdue Pharma Lp Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
AR091779A1 (es) * 2012-07-16 2015-02-25 Rhodes Technologies Procedimiento para la sintesis mejorada de opioides
UA117225C2 (uk) 2012-07-16 2018-07-10 Родес Текнолоджіс Спосіб покращеного синтезу опіоїду
CA2880446C (en) * 2012-08-03 2018-03-13 Johnson Matthey Public Limited Company A method for preparing oxycodone
ES2691982T3 (es) 2012-11-30 2018-11-29 Acura Pharmaceuticals, Inc. Liberación autorregulada de un principio activo farmacéutico
AP2015008579A0 (en) 2013-02-05 2015-07-31 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
WO2014130714A1 (en) * 2013-02-20 2014-08-28 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
WO2015015146A1 (en) 2013-08-02 2015-02-05 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
PL3065743T3 (pl) 2013-11-07 2019-12-31 SpecGx LLC Sposób wytwarzania 6-hydroksymorfinanów bez izolowania związków pośrednich
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
JP2017502991A (ja) 2014-01-15 2017-01-26 ローズ テクノロジーズ 改良されたオキシコドン合成のための方法
KR101868724B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시모르폰 합성을 위한 방법
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
MA40332A (fr) 2014-07-09 2021-04-28 Rhodes Tech Réduction des niveaux de cétone alpha, beta-insaturée dans des compositions de dérivés de morphinane
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) * 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018055199A1 (en) 2016-09-26 2018-03-29 Euro-Celtique S.A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN110770238B (zh) * 2017-06-20 2022-10-04 庄信万丰股份有限公司 用于从14-羟可待因酮制备盐酸氧可酮的氢化方法
JP2020526500A (ja) 2017-06-30 2020-08-31 パーデュー、ファーマ、リミテッド、パートナーシップ 治療方法及びその剤形
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US420098A (en) * 1890-01-28 Mowing-machine
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
DE286431C (enExample)
US1468805A (en) 1923-09-25 Htabtin ereund
US1485673A (en) 1924-03-04 Ministrator
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
DE296916C (enExample) *
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (enExample) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (enExample) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) * 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4272540A (en) * 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) * 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) * 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4639520A (en) * 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) * 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4810669A (en) * 1987-07-07 1989-03-07 Oki Electric Industry Co., Ltd. Method of fabricating a semiconductor device
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
EP2272536B1 (en) 1996-06-26 2016-05-04 Board of Regents, The University of Texas System Hot-melt extrudable Pharmaceutical formulation
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
DE69911802T2 (de) * 1998-10-14 2004-07-29 Gyros Ab Form und verfahren zu deren herstellung
US6177567B1 (en) 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
EP2517710B1 (en) * 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
WO2001092188A1 (en) 2000-05-29 2001-12-06 Shionogi & Co., Ltd. Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
DE60239801D1 (de) * 2001-06-05 2011-06-01 Control Delivery Systems Watertown Analgetika mit verzögerter wirkstoffabgabe
WO2002100382A2 (en) 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
CA2454328C (en) 2001-07-18 2008-03-18 Christopher D. Breder Pharmaceutical combinations of oxycodone and naloxone
EP1474198B1 (en) * 2002-01-15 2015-12-30 Novartis AG System for clearing aerosols from the effective anatomic dead space
JP4790219B2 (ja) * 2002-03-26 2011-10-12 ユーロ−セルティーク エス.エイ. 徐放性ゲルコーティング組成物
CA2483655A1 (en) 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
JP3811491B2 (ja) * 2002-05-27 2006-08-23 株式会社エヌ・ティ・ティ・ドコモ 移動通信システム、送信局、受信局、中継局および通信経路決定方法
MXPA04012021A (es) 2002-05-31 2005-08-16 Johnson & Johnson Formas de dosis y composiciones para la administracion osmotica de dosis variables de oxicodona.
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
WO2004016618A1 (en) * 2002-08-15 2004-02-26 Noramco, Inc. Oxycodone-hydrochloride polymorhs
WO2004045551A2 (en) 2002-11-15 2004-06-03 Branded Products For The Future Pharmaceutical composition
CA2507851A1 (en) * 2002-11-29 2004-06-17 Forest Laboratories, Inc. Combination of ibuprofen and oxycodone for acute pain relief
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
DE602004024963D1 (de) 2003-03-13 2010-02-25 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US6864370B1 (en) 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070172958A1 (en) * 2004-03-30 2007-07-26 Euro-Celtique S.A. Methods for detecting 14-hydroxy codeinone and codeinone
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
JP5329083B2 (ja) 2004-06-25 2013-10-30 テッセラ,インコーポレイテッド ポストおよびパッドを有する部品
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
ME01594B (me) 2005-03-04 2014-09-20 Euro Celtique Sa Postupak smanjenja alfa, beta nezasićenih ketona u opioidnim kompozicijama
ES2357216T3 (es) 2005-06-16 2011-04-20 Mallinckrodt, Inc. Una ruta de síntesis de 14-hidroxil-opiáceos a través de 1-halo-tebaína o análogos.
KR101417135B1 (ko) 2005-11-22 2014-07-08 콘드롤드 케미컬즈, 인크. 옥시코돈 및 다른 조성물에서 오염물질인 마이클 수용체수준을 감소시키는 방법
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
CN101395159A (zh) 2006-03-02 2009-03-25 马林克罗特公司 制备含有低含量α,β-不饱和酮化合物的吗啡烷-6-酮产物的方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
ES2378710T3 (es) 2006-12-04 2012-04-17 Noramco, Inc. Procedimiento para reducir impurezas en la base de oxicodona
CA2671518C (en) 2006-12-04 2016-06-07 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
EP2588481B1 (en) 2010-07-02 2017-11-15 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Similar Documents

Publication Publication Date Title
JP2018184462A5 (enExample)
JP2012072162A5 (enExample)
JP2017509667A5 (enExample)
JP2019516735A5 (enExample)
MA45052A (fr) Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
JP2014507446A5 (enExample)
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
JP2013173782A5 (enExample)
JP2013519675A5 (enExample)
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
JP2016106149A5 (enExample)
JP2013507408A5 (enExample)
JP2016509051A5 (enExample)
JP2015537009A5 (enExample)
JP2016540030A5 (enExample)
IL242143B (en) A pharmaceutical preparation for oral administration for the prevention or treatment of dry eye syndrome, containing rabamifid or its prodrug
HUE057216T2 (hu) Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében
JP2017518982A5 (enExample)
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
JP2019515942A5 (enExample)
JP2019518052A5 (enExample)
LT3429616T (lt) Kompozicijos, skirtos snukio ir nagų ligų gydymui ir prevencijai
JP2018513862A5 (enExample)
JP2015514742A5 (enExample)
JP2017515849A5 (enExample)